Meanwhile, Intercept Pharma’s obeticholic acid ... that elafibranor’s failure in NASH shouldn’t read through to its potential in PBC – a chronic, autoimmune disease in which bile ...

Ipsen has taken rights to PPAR agonist elafibranor as a treatment for primary biliary cholangitis – a chronic, autoimmune disease in which bile ducts ... obeticholic acid – still a hopeful ...